BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.
BSX - Boston Scientific Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$66.30
DETAILS
HIGH:
$100.00
LOW:
$50.00
MEDIAN:
$63.50
CONSENSUS:
$66.30
UPSIDE:
52.98%
Stock News
Boston Scientific Corporation $BSX Shares Acquired by Corient Private Wealth LP
Corient Private Wealth LP increased its stake in shares of Boston Scientific Corporation (NYSE: BSX) by 25.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 233,728 shares of the medical equipment provider's stock after acquiring an additional 47,125 shares during
New Strong Sell Stocks for September 16th
AGCO, BSX and BBWI have been added to the Zacks Rank #5 (Strong Sell) List on September 16th, 2026.
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade)
Boston Scientific is upgraded to 'Strong Buy' as market overreaction creates an attractive entry point for long-term investors. BSX trades at a forward P/E of 13.1, well below its historical average, despite robust profitability and solid Q2 2026 results. Growth headwinds from WATCHMAN and electrophysiology are offset by strong Interventional Cardiology and Vascular Therapies momentum.
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth
BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.
Boston Scientific: $43 Finally Prices In A Bad 2026
Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns.
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Boston Scientific (BSX) reached $43.1 at the closing of the latest trading day, reflecting a -4.14% change compared to its last close.
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Restores Key Operations After Cyberattack
The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.
Boston Scientific Corporation $BSX Shares Acquired by Concurrent Investment Advisors LLC
Concurrent Investment Advisors LLC boosted its holdings in Boston Scientific Corporation (NYSE: BSX) by 77.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 55,565 shares of the medical equipment provider's stock after purchasing an additional 24,166 shares during the quarter. Concurrent
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
Boston Scientific Corporation (NYSE:BSX) anticipates a material hit to its third-quarter and full-year 2026 financial results following an August cybersecurity incident that disrupted global operations.
Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?
BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.
Stock Futures Mixed to Start Holiday-Shortened Week
Stock futures are mixed to start the shortened week as oil prices rise
Boston Scientific ‘Unlikely to Meet' Earnings Guidance After Cyberattack. Stock Falls.
Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Boston Scientific Won't Meet Guidance Due to Cyberattack
Boston Scientific said it likely won't meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Boston Scientific says cyberattack likely to hurt 2026 sales, profit
Boston Scientific said on Tuesday a cybersecurity incident that disrupted manufacturing and order shipments globally is likely to have a material impact on its third-quarter and full-year 2026 results.
AlphaGrep UK Ltd Makes New $978,000 Investment in Boston Scientific Corporation $BSX
AlphaGrep UK Ltd acquired a new position in shares of Boston Scientific Corporation (NYSE: BSX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,906 shares of the medical equipment provider's stock, valued at approximately $978,000. Other large investors
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.
Price Targets
Boston Scientific price target lowered to $56 from $60 at BTIG
$56.00
(was $44.98)
Marie Thibault
·
BTIG
Boston Scientific price target lowered to $70 from $85 at RBC Capital
$70.00
(was $44.80)
Shagun Singh
·
RBC Capital
Boston Scientific price target lowered to $67 from $74 at UBS
$67.00
(was $44.90)
UBS
Boston Scientific price target lowered to $60 from $75 at Deutsche Bank
$60.00
(was $44.93)
Pito Chickering
·
Deutsche Bank
Boston Scientific price target lowered to $56 from $64 at Baird
$56.00
(was $46.04)
Robert W. Baird
Boston Scientific price target lowered to $66 from $70 at Canaccord
$66.00
(was $46.04)
Canaccord Genuity
Boston Scientific price target lowered to $50 from $55 at Wells Fargo
$50.00
(was $46.04)
Wells Fargo
Boston Scientific price target lowered to $60 from $74 at Leerink
$60.00
(was $46.04)
Leerink Partners
Boston Scientific (BSX) PT Lowered to $57 at Raymond James
$57.00
(was $46.04)
Jayson Bedford
·
Raymond James
Boston Scientific (BSX) PT Lowered to $60 at BTIG
$60.00
(was $46.04)
Marie Thibault
·
BTIG
Boston Scientific price target lowered to $60 from $65 at Stifel
$60.00
(was $46.55)
Rick Wise
·
Stifel Nicolaus
Boston Scientific assumed with a Buy at UBS
$74.00
(was $45.51)
UBS
Boston Scientific price target lowered to $85 from $90 at Oppenheimer
$85.00
(was $45.88)
Oppenheimer
Boston Scientific price target lowered to $62 from $64 at Truist
$62.00
(was $44.59)
Truist Financial
Boston Scientific price target lowered to $70 from $90 at Mizuho
$70.00
(was $42.63)
Anthony Petrone
·
Mizuho Securities
Boston Scientific price target lowered to $85 from $100 at RBC Capital
$85.00
(was $44.72)
Shagun Singh
·
RBC Capital
Boston Scientific (BSX) PT Lowered to $57 at Needham
$57.00
(was $45.30)
Mike Matson
·
Needham
Boston Scientific price target lowered to $65 from $78 at Evercore ISI
$65.00
(was $44.55)
Evercore ISI
Boston Scientific price target lowered to $65 from $75 at Stifel
$65.00
(was $44.46)
Stifel Nicolaus
Boston Scientific price target lowered to $65 from $90 at Piper Sandler
$65.00
(was $47.17)
Piper Sandler